CAR-T and Cellular Therapy Promises Long-Lasting Lupus Remission
Key Questions
What were the key results of the UK NHS trial using obe-cel CAR-T therapy for severe lupus?
In the trial, 5 out of 6 patients with severe lupus achieved remission lasting over 18 months and were able to discontinue all medications. The therapy is described as an autologous CD19 CAR-T treatment that resets the immune system.
Who is Katie Tinkler and how does her story relate to the lupus CAR-T trial?
Katie Tinkler is a patient who participated in the NHS trial and reported significant improvement, stating she has 'never been this good' after the immune reset treatment. Her experience provides a personal perspective on the therapy's impact for severe lupus.
Which other CAR-T or cellular therapy programs are advancing for lupus treatment?
Programs include Fate's FT819 Phase 1 with new lupus nephritis trial plans, Cabaletta's Rese-Cel advancing to pivotal studies, Cullinan's CLN-978 Phase 1 showing deep B cell depletion, and Imviva's allogeneic dual-target CAR-T cleared for Phase 1b by the FDA.
What recent data supports Cullinan Therapeutics' CLN-978 in autoimmune diseases?
Initial clinical data from the Phase 1 OUTRACE trial presented at EULAR showed deep B cell depletion and remissions in patients, with a subcutaneous administration route. The company also highlighted cash runway extending to 2027 and a manufacturing deal with Cellares.
What is Imviva's CTA313 and its regulatory status for autoimmune diseases?
CTA313 is an allogeneic dual-target CAR-T therapy that received FDA clearance for a Phase 1b trial in autoimmune diseases including lupus. This adds to the growing pipeline of off-the-shelf cellular therapies.
How is CAR-T therapy being explored beyond lupus remission, such as in kidney transplants?
A Reuters report notes CAR-T's potential dual role in achieving deep tissue remission in SLE and supporting kidney transplant outcomes. This expands the therapeutic applications discussed in recent coverage.
Are there new funding or mechanistic studies for CAR-T in lupus?
The Lupus Research Alliance and Genentech are funding three mechanistic studies to better understand CAR-T effects. Additionally, a MUSC Phase 2 mesenchymal stem cell trial has been completed.
What is the status of Beijing Boren and UCB programs mentioned in lupus cellular therapy developments?
Beijing Boren is conducting a Phase 1 trial of BCMA+CD19 CAR-T, while UCB's $2.2 billion investment in cizutimig further reinforces industry momentum in this area.
Major breakthrough: UK NHS trial of obe-cel (autologous CD19 CAR-T) shows 5/6 severe lupus patients in remission after 18+ months, off all medications—patient Katie Tinkler's story adds powerful human angle. Other programs: Fate FT819 Ph1 incl. new LN trial plans, Cabaletta Rese-Cel advancing pivotal with cash to 2027/Cellares deal/EULAR data, new in-vivo mRNA from UPenn/Capstan, Cullinan CLN-978 Ph1 OUTRACE with initial data showing deep B cell depletion and remissions, subcutaneous route; Beijing Boren BCMA+CD19 Ph1; UCB $2.2B cizutimig reinforces momentum. LRA and Genentech fund three mechanistic studies. MUSC Phase 2 MSC trial completed. New Reuters piece highlights CAR-T's dual role in kidney transplants and SLE deep tissue remission. Imviva's allogeneic dual-target CAR-T (CTA313) gets FDA clearance for Ph1b.